Investor Relations
19 March 2021 (Friday)
2020 Annual Results Announcement Investor Briefing
Dear Investors and Analysts,
On behalf of Hua Medicine (2552.HK), we cordially invites you or your representative to attend the Company's 2020 annual results investor briefing webcasting. The management team of the Company will review the business and financial performance in 2020 and share with you its future outlook.
Date: | 19 March 2021 (Friday) |
Time: |
3:00 PM HKT |
Language: | English |
Management: |
Dr. Li Chen, Chief Scientific Officer and Executive Director |
Format: | Zoom Webcasting |
Dial-in Details: | https://icaasia.zoom.us/ webinar/register/ WN_OGK-u0WKRb2J85dMWlVbKA |
Q&A: | There will be a Q&A session. Feel free to send your questions to yhlee@icaasia.com prior to the webcasting. |
Company Profile: | Hua Medicine is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua Medicine advanced a first-in-class oral drug for the treatment of T2DM into NDA-enabling stage and it has successfully completed two Phase III registration trials in China for dorzagliatin. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide. |
滬ICP備14036654號-1
滬公網(wǎng)安備 31011502013809號 Privacy Statement Terms of Use
